1. Structural basis for C-degron selectivity across KLHDCX family E3 ubiquitin ligases.
- Author
-
Scott DC, Chittori S, Purser N, King MT, Maiwald SA, Churion K, Nourse A, Lee C, Paulo JA, Miller DJ, Elledge SJ, Harper JW, Kleiger G, and Schulman BA
- Subjects
- Substrate Specificity, Humans, Crystallography, X-Ray, Cryoelectron Microscopy, Protein Binding, Models, Molecular, Ubiquitin metabolism, Amino Acid Motifs, Degrons, Ubiquitin-Protein Ligases metabolism, Ubiquitin-Protein Ligases chemistry, Ubiquitin-Protein Ligases genetics, Ubiquitination
- Abstract
Specificity of the ubiquitin-proteasome system depends on E3 ligase-substrate interactions. Many such pairings depend on E3 ligases binding to peptide-like sequences - termed N- or C-degrons - at the termini of substrates. However, our knowledge of structural features distinguishing closely related C-degron substrate-E3 pairings is limited. Here, by systematically comparing ubiquitylation activities towards a suite of common model substrates, and defining interactions by biochemistry, crystallography, and cryo-EM, we reveal principles of C-degron recognition across the KLHDCX family of Cullin-RING ligases (CRLs). First, a motif common across these E3 ligases anchors a substrate's C-terminus. However, distinct locations of this C-terminus anchor motif in different blades of the KLHDC2, KLHDC3, and KLHDC10 β-propellers establishes distinct relative positioning and molecular environments for substrate C-termini. Second, our structural data show KLHDC3 has a pre-formed pocket establishing preference for an Arg or Gln preceding a C-terminal Gly, whereas conformational malleability contributes to KLHDC10's recognition of varying features adjacent to substrate C-termini. Finally, additional non-consensus interactions, mediated by C-degron binding grooves and/or by distal propeller surfaces and substrate globular domains, can substantially impact substrate binding and ubiquitylatability. Overall, the data reveal combinatorial mechanisms determining specificity and plasticity of substrate recognition by KLDCX-family C-degron E3 ligases., Competing Interests: Competing interests D.C.S. and B.A.S. are co-inventors of intellectual property that is unrelated to this work (DCN1 inhibitors licensed to Cinsano). J.W.H. is a founder and consultant for Caraway Therapeutics and is a scientific advisory board member for Lyterian Therapeutics. SJE is a founder of, and holds equity in TScan Therapeutics and Immune ID. S.J.E. is also founder of MAZE Therapeutics, and Mirimus and serves on the scientific advisory board of TSCAN Therapeutics, and MAZE Therapeutics. In accordance with Partners HealthCare’s conflict of interest policies, the Partners Office for Interactions with Industry has reviewed SJE’s financial interest in TSCAN and determined that it creates no significant risk to the welfare of participants in this study or to the integrity of this research. B.A.S. is a member of the scientific advisory boards of Biotheryx and Proxygen. The remaining authors declare no competing interests., (© 2024. The Author(s).)
- Published
- 2024
- Full Text
- View/download PDF